A Philadelphia jury yesterday ordered Johnson & Johnson subsidiary Janssen to pay $11 million to the parents of a five-year-old boy for failure to warn doctors of potential birth defects associated with its epilepsy drug Topamax. “Janssen knew about Topamax’s serious risk of causing birth defects years before these mothers were prescribed the drug, but did not advise physicians of those risks,” said the family’s lawyers in a press release. The case is the second of about 134 pending in Philadelphia.
Of further interest:
J&J Ordered to Pay $10M Topamax Verdict (Press Release)
Philly jury hits J&J with $11M verdict in Topamax birth-defects case (Fierce Pharma)
Editor’s note: this posting has been updated with new information.